| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10911-009-9113-0 |
| P698 | PubMed publication ID | 19263197 |
| P2093 | author name string | Dorraya El-Ashry | |
| Joeli A Brinkman | |||
| P2860 | cites work | A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines | Q71635509 |
| MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo | Q71989512 | ||
| Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I | Q72093197 | ||
| Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells | Q72386166 | ||
| Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition | Q73393598 | ||
| Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer | Q73483264 | ||
| Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis | Q73555066 | ||
| Protein synthesis is not implicated in the ligand-dependent activation of the estrogen receptor in MCF-7 cells | Q73962650 | ||
| Estradiol regulates estrogen receptor mRNA stability | Q77157673 | ||
| Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors | Q77556929 | ||
| Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer | Q93886960 | ||
| Oestrogen receptor expression in the normal and pre-cancerous breast | Q93924363 | ||
| Worms gang up on bacteria | Q27860588 | ||
| Signal transduction by receptors with tyrosine kinase activity | Q27860624 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation | Q28140491 | ||
| Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors | Q29616455 | ||
| The human estrogen receptor has two independent nonacidic transcriptional activation functions | Q29617089 | ||
| Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase | Q29617567 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Gene regulation by steroid hormones | Q29618291 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death | Q29620021 | ||
| Structure, regulation and function of NF-kappa B | Q29620225 | ||
| Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer | Q33845160 | ||
| The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation | Q33911291 | ||
| Estrogen responsiveness and control of normal human breast proliferation. | Q33923670 | ||
| Histological and biological evolution of human premalignant breast disease | Q34249797 | ||
| Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. | Q34300189 | ||
| Signalling by receptor tyrosine kinases | Q34306539 | ||
| Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications | Q34453019 | ||
| Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy | Q34480666 | ||
| Altered methylation patterns in cancer cell genomes: cause or consequence? | Q34710435 | ||
| The biology of breast carcinoma | Q35053948 | ||
| MAP kinase by any other name smells just as sweet | Q35224916 | ||
| Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression | Q35253399 | ||
| NF-kappaB in mammary gland development and breast cancer | Q35592117 | ||
| Erks: their fifteen minutes has arrived | Q35709102 | ||
| Estrogen receptor-positive proliferating cells in the normal and precancerous breast. | Q35787982 | ||
| Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. | Q35834174 | ||
| Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation | Q35849279 | ||
| Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer | Q35868817 | ||
| Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer | Q35979084 | ||
| Oestrogen and progesterone receptor distribution in the cancerous breast | Q36027980 | ||
| Malignant and benign human mammary disease: estrogen binding in relation to clinical data | Q36513175 | ||
| Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth | Q36569036 | ||
| Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression | Q36620956 | ||
| Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor | Q37021857 | ||
| Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland | Q37094546 | ||
| E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors | Q37146105 | ||
| Proteasome-dependent degradation of the human estrogen receptor | Q37160826 | ||
| How to use prognostic factors in axillary node-negative breast cancer patients | Q37928790 | ||
| Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. | Q38292576 | ||
| Steroid receptors and other prognostic factors in primary breast cancer | Q39641033 | ||
| Steroid receptor regulated transcription of specific genes and gene networks | Q39838638 | ||
| Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells | Q39953544 | ||
| ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor | Q40014619 | ||
| Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. | Q40041160 | ||
| Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation | Q40195308 | ||
| Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer | Q40243239 | ||
| Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors | Q40296280 | ||
| Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. | Q40530132 | ||
| A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. | Q40571380 | ||
| Transcriptional regulation by extracellular signals: mechanisms and specificity | Q40579098 | ||
| Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors | Q40773290 | ||
| Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors | Q41044835 | ||
| Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells | Q41070371 | ||
| Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells | Q41184313 | ||
| Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. | Q41342928 | ||
| Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression | Q41425086 | ||
| Nuclear receptor coactivators and corepressors | Q41447637 | ||
| Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action | Q41546396 | ||
| Expression of estrogen receptor and its messenger ribonucleic acid in the MCF-7 cell line: multiparametric analysis of its processing and regulation by estrogen | Q41714899 | ||
| c-erbB-2 oncogene as a prognostic marker in breast cancer | Q42383432 | ||
| Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF-7 breast cancer cells | Q42505128 | ||
| Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells | Q42507632 | ||
| Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. | Q42524053 | ||
| Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways | Q42815884 | ||
| Activation of NF-kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade | Q42826970 | ||
| Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity | Q43503793 | ||
| Epidermal growth factor receptors on human breast cancers | Q43710325 | ||
| Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. | Q43755864 | ||
| Ovarian hormone receptors in human mammary stromal cells | Q43762839 | ||
| Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans. | Q44205873 | ||
| Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. | Q44220774 | ||
| Estradiol stabilizes estrogen receptor messenger ribonucleic acid in sheep endometrium via discrete sequence elements in its 3'-untranslated region | Q44294718 | ||
| Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. | Q44653608 | ||
| A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. | Q44657529 | ||
| Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer | Q44750877 | ||
| Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors | Q45060020 | ||
| Co-activators and co-repressors in the integration of transcriptional responses | Q46623959 | ||
| Dissociation between steroid receptor expression and cell proliferation in the human breast. | Q52528046 | ||
| Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. | Q53409303 | ||
| Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. | Q54116914 | ||
| HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. | Q54170195 | ||
| Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers | Q54977499 | ||
| The fundamental role of epigenetic events in cancer | Q56421597 | ||
| Predictors of response to second-line endocrine therapy for breast cancer | Q58834601 | ||
| DNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells | Q60191846 | ||
| Relationship between proliferative activity and estrogen receptors in breast cancer | Q66921825 | ||
| Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer | Q67710267 | ||
| Regulation of the estrogen receptor in MCF-7 cells by estradiol | Q68015751 | ||
| [Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients] | Q68304236 | ||
| Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases | Q68747791 | ||
| Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer | Q68968128 | ||
| Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels | Q69495721 | ||
| Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer | Q69900051 | ||
| Steroid hormone receptors and carcinoma of the breast | Q70443941 | ||
| Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique | Q71251039 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 67-78 | |
| P577 | publication date | 2009-03-05 | |
| P1433 | published in | Journal of Mammary Gland Biology and Neoplasia | Q15724460 |
| P1476 | title | ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers | |
| P478 | volume | 14 |
| Q34272080 | Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. |
| Q35091502 | Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors |
| Q28243823 | Combined genetic and nutritional risk models of triple negative breast cancer |
| Q34431099 | Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3. |
| Q33917455 | Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. |
| Q38656581 | Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression |
| Q44384358 | ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer |
| Q90222199 | ERα is required for suppressing OCT4-induced proliferation of breast cancer cells via DNMT1/ISL1/ERK axis |
| Q37992693 | Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q33743983 | Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. |
| Q35667708 | Headway in resistance to endocrine therapy in breast cancer |
| Q39707882 | Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. |
| Q36568751 | Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells |
| Q36295330 | Inhibition of EGFR autophosphorylation plays an important role in the anti-breast cancer efficacy of the dithiocarbamate derivative TM208. |
| Q34946215 | MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis |
| Q39340427 | MTA1 expression correlates significantly with ER-alpha methylation in breast cancer |
| Q35571726 | Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus. |
| Q36851417 | Mechanisms of Endocrine Resistance in Breast Cancer |
| Q37962015 | Modulation of gene expression in ovarian cancer by active and repressive histone marks |
| Q37649668 | Overexpression of 14-3-3θ promotes tumor metastasis and indicates poor prognosis in breast carcinoma |
| Q35690099 | PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype |
| Q26825056 | Potential roles for prions and protein-only inheritance in cancer |
| Q51666148 | Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer. |
| Q36645071 | Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. |
| Q54348663 | Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients. |
| Q35998100 | Regulation of STAT signaling by acetylation |
| Q35833879 | Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines |
| Q38485889 | Targeting JAK kinase in solid tumors: emerging opportunities and challenges |
| Q37269461 | Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review). |
| Q38965387 | Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. |
| Q89638568 | UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer |
| Q36021424 | Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. |
| Q33710113 | Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa |
| Q33815885 | ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer |
Search more.